Anavex Life Sciences Corp.AVXL
Price (close)
$2.38
Market cap
$212.6M
P/E
—
Revenue (TTM)
—
Net income
-$13.0M
Dividend yield
—
1-year total return
-72.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What Anavex Life Sciences Corp. does.
company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (“CNS”)
diseases with high unmet need. We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our
treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$26.3M | -$37.9M | -$48.0M | -$47.5M | -$43.0M | -$46.4M |
| Free cash flow | — | — | — | — | — | — |
More on AVXL.
- Anavex Life Sciences Corp. summary
- Anavex Life Sciences Corp. financial statements
- Anavex Life Sciences Corp. key metrics
- Anavex Life Sciences Corp. health scores and style box
- Anavex Life Sciences Corp. earnings
- Anavex Life Sciences Corp. dividends
- Anavex Life Sciences Corp. valuation
- Anavex Life Sciences Corp. ownership and insiders
- Anavex Life Sciences Corp. peers
Figures from Anavex Life Sciences Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.